1. Home
  2. /
  3. Projects
  4. /
  5. Page 6

Availability

Availability refers to sufficient, sustainable and timely supply of new TB vaccines for adults and adolescents. This includes having demand assessed for different population groups, defining policy and evidence needs, and having procurement plans in plans. This follows from the WHO global framework for country introduction of new adolescent and adult TB vaccines (https://www.who.int/publications/m/item/who-global-framework-to-prepare-for-country-introduction-of-new-tb-vaccines-for-adults-and-adolescents)

Preferred product characteristics for new tuberculosis vaccine

The document presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy. Priorities are for a vaccine to be administered to adolescents and adults for prevention of pulmonary tuberculosis and reduction of transmission, and for a pediatric vaccine with improved safety and efficacy as compared to BCG.

Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes

The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for ev idence generation and discusses key considerations about potential clinical development strategies
Click to copy link of this header Menu